MEI Pharma, Inc.: MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical
United States Asia Pacific Andrew David Zelenetz Jacob Drobnyk Soumerai Davida Walsey Public Affairs Kyowa Kirin North America
Source: finanznachrichten.de